UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040660
Receipt number R000046405
Scientific Title Exploratory analysis of gene profiling and immunohistochemical marker in male breast cancer.
Date of disclosure of the study information 2020/06/08
Last modified on 2022/12/25 17:35:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory analysis of gene profiling and immunohistochemical marker in male breast cancer.

Acronym

Exploratory analysis of gene profiling and immunohistochemical marker in male breast cancer.

Scientific Title

Exploratory analysis of gene profiling and immunohistochemical marker in male breast cancer.

Scientific Title:Acronym

Exploratory analysis of gene profiling and immunohistochemical marker in male breast cancer.

Region

Japan


Condition

Condition

Male Breast Cancer

Classification by specialty

Hematology and clinical oncology Breast surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Identifying genetic profiling and immunohistochemical markers specific to male breast cancer

Basic objectives2

Others

Basic objectives -Others

Translational research

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Descriptive statistics of comprehensive gene panel analysis, BRCA1 gene methylation analysis, and immunohistochemical marker analysis of male breast cancer specimens

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1) Patients who have been diagnosed with male breast cancer
2) Patients who are 20 years of age or older at the time of diagnosis
3) Patients who have a sufficient quantity of specimens (approximately 30 4u thick unstained specimens) collected during the study period in question for measurement.

Key exclusion criteria

Patients who have decided inappropriate to include in this study by the investigators

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Akihiko
Middle name
Last name Shimomura

Organization

National Center for Global Health and Medicine

Division name

Breast and Medical Oncology

Zip code

162-8655

Address

1-21-1 Toyama, Shinjuku-ku Tokyo

TEL

03-3202-7181

Email

akshimomura@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name Akihiko
Middle name
Last name Shimomura

Organization

National Center for Global Health and Medicine

Division name

Breast and Medical Oncology

Zip code

162-8655

Address

1-21-1 Toyama, Shinjuku-ku Tokyo

TEL

03-3202-7181

Homepage URL


Email

akshimomura@hosp.ncgm.go.jp


Sponsor or person

Institute

National Center for Global Health and Medicine

Institute

Department

Personal name



Funding Source

Organization

Chugai Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of the National Center for Global Health and Medicine

Address

1-21-1 Toyama, Shinjuku-ku Tokyo

Tel

03-3202-7181

Email

rinrijm@hosp.ncgm.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 06 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

103

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 04 Month 20 Day

Date of IRB

2020 Year 05 Month 20 Day

Anticipated trial start date

2020 Year 05 Month 20 Day

Last follow-up date

2021 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

A retrospective study in which specimens and clinicopathological information from the principal investigator and subordinate institutions are collected and measured


Management information

Registered date

2020 Year 06 Month 05 Day

Last modified on

2022 Year 12 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046405


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name